Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol
Renato Bassan(Pittini Group (Italy)), Robin Foà(Sapienza University of Rome), Francesca Paoloni(Fondazione Gimema Onlus), Anna Maria Scattolin(Ospedale dell' Angelo), Paola Fazi(Fondazione Gimema Onlus), Nicola Cascavilla, Sabina Chiaretti(Sapienza University of Rome), Paola Perfetti(Azienda Ospedaliera San Gerardo), Martina Canichella(ASL Roma), Elisa Cerqui(San Antonio College), Irene Della Starza(Associazione Italiana Ematologia Oncologia Pediatrica), Marco Vignetti(Fondazione Gimema Onlus), Mario Delia(University of Bari Aldo Moro), Francesco Fabbiano(San Antonio College), Ernesta Audisio(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Monica Fumagalli(Azienda Ospedaliera San Gerardo), Antonella Vitale(University of the Sacred Heart), Stefania Paolini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Caterina Micò(Azienda Ospedaliero-Universitaria delle Marche), Mariangela Iodice(Fondazione Gimema Onlus)
Cited by 7
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644